Intelligencia Raises $12M To Reduce The Risk Of Clinical Research, Improve R&Amp;D Productivity, And Accelerate Scientific Breakthroughs

Intelligencia, whose AI-driven software platform enables pharmaceutical and biotechnology companies to revolutionize the drug development process and reduce risk, has raised $12M in order to continue to expand its product offering and customer base. Healthtech investor MTIP led the oversubscribed Series A round, joined by several of the company’s existing investors, including Big Pi Ventures and Synetro Group. ZS, a global professional services firm that leverages deep analytics and biopharmaceutical industry expertise to help companies and their customers thrive, has also participated in this round.